The document discusses the use of maintrac® liquid biopsy to test circulating epithelial tumor cells (CETCs) for chemosensitivity in patients, particularly focusing on identifying the most effective therapeutic drugs. It presents data from 62 patients, revealing sensitivity rates to several drugs, including doxorubicin, epirubicin, and curcumin. Additionally, it emphasizes that increasing cell numbers suggest the necessity of chemosensitivity testing to optimize treatment efficiency.

1. Maintrac®
Liquid biopsy
circulating epithelial tumor cells
Transfusion Medicine Center Bayreuth TZB, Germany

2. Increasing cell numbers
identify patients likely to be at increased risk for
serious side effects as a result of treatment with a
particular therapeutic product

3. Chemo-
sensitivity
J Cancer Therapy 2013, 4:597-
605
Chemosensitivity Testing of
Circulating Epithelial Tumor
Cells (CETC) in Vitro:
Correlation to in Vivo
Sensitivity and Clinical
Outcome.

4. Chemo-
sensitivity
• Subdividing and exposing the
blood sample to different
drugs and concentrations
• Determining the rate of dying
circulating epithelial tumor
cells to identify the most
effective drug for the patient

5. The mortality rate of the CETCs measured
over the time in the presence of medication
3h 6h 9h

7. Patients total: 62
Sensitivity > 50% 39 Patients 63%
Sensitivity < 50% 23 Patients 37%
Doxorubicin
0
10
20
30
40
50
60
70
80
90
100
1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61
Patientenanzahl
Ansprechrate%

8. Patients total: 66
Sensitivity > 50% 34 Patients 52%
Sensitivity < 50% 32 Patients 48%
Epirubicin
0
10
20
30
40
50
60
70
80
90
100
1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52 55 58 61 64 67
Patientenanzahl
Ansprechrate%

9. Patients total: 51
Sensitivity > 50% 16 Patients 31%
Sensitivity < 50% 35 Patients 69%
DCA
0
10
20
30
40
50
60
70
80
90
100
1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49
Patientenanzahl
Ansprechrate%

10. Curcumin
0
10
20
30
40
50
60
70
80
90
100
1 4 7 10 13 16 19 22 25 28 31 34 37 40 43 46 49 52
Patientenanzahl
Ansprechrate%
Patients total: 52
Sensitivity > 50% 39 Patients 75%
Sensitivity < 50% 13 Patients 25%

11. Relapse free survial of patients
with ovarian cancer
Sensitive vs.
resistant tumor
cells to standard
therapy
(carboplatin and
paclitaxel)

13. If cell numbers are
increasing,
chemosensitivity
testing can be
considered to
determine the drug
with the best
efficiency.

14. Thanks for your attention!
Prof. Katharina Pachmann
kpachmann@laborpachmann.de
+49 921 850200

15. SIMFO Specialized Immunology Research + Development GmbH
& Laboratory Dr. Ulrich Pachmann
Kurpromenade 2
95448 Bayreuth
Germany
www.maintrac.com